TY - JOUR
T1 - Recommendations for radiotherapy quality assurance in clinical trials
AU - Nielsen, Camilla Panduro
AU - Samsøe, Eva
AU - Offersen, Birgitte Vrou
AU - Lorenzen, Ebbe Laugaard
AU - Persson, Gitte
AU - Mortensen, Hanna Rahbek
AU - Nissen, Henrik Dahl
AU - Vogelius, Ivan Richter
AU - Kallehauge, Jesper Folsted
AU - Muren, Ludvig Paul
AU - Brincker, Mads
AU - Felter, Mette van Overeem
AU - Dahlrot, Rikke Hedegaard
AU - Hokland, Steffen Bjerre
AU - Schytte, Tine
AU - Havelund, Birgitte Mayland
AU - Weber, Britta
AU - Møller, Ditte Sloth
AU - Serup-Hansen, Eva
AU - Jensen, Kenneth
AU - Jakobsen, Kirsten Legård
AU - Josipovic, Mirjana
AU - Krogh, Simon Long
AU - Lukacova, Slávka
AU - Hoffmann, Lone
AU - Hansen, Christian Rønn
N1 - Copyright © 2025 The Author(s). Published by Elsevier B.V. All rights reserved.
PY - 2025/5/22
Y1 - 2025/5/22
N2 - Robust quality assurance (QA) of clinical trials in radiotherapy (RT) is paramount for minimising uncertainties in treatment delivery, thereby strengthening the statistical power of the study and increasing the likelihood of accurately answering the research question. As RT techniques evolve and become more complex, establishing an appropriate QA program for a specific clinical trial becomes increasingly challenging, highlighting the importance of clear and standardised recommendations. This study provide such recommendations for Principal Investigators (PIs) to consider when planning and conducting RT Quality Assurance (RTQA) for clinical trials. They arise from experiences with RTQA in the clinical trials conducted in the Danish Multidisciplinary Cancer Groups (DMCGs). The recommendations include a checklist to guide PIs in developing an effective RTQA program.
AB - Robust quality assurance (QA) of clinical trials in radiotherapy (RT) is paramount for minimising uncertainties in treatment delivery, thereby strengthening the statistical power of the study and increasing the likelihood of accurately answering the research question. As RT techniques evolve and become more complex, establishing an appropriate QA program for a specific clinical trial becomes increasingly challenging, highlighting the importance of clear and standardised recommendations. This study provide such recommendations for Principal Investigators (PIs) to consider when planning and conducting RT Quality Assurance (RTQA) for clinical trials. They arise from experiences with RTQA in the clinical trials conducted in the Danish Multidisciplinary Cancer Groups (DMCGs). The recommendations include a checklist to guide PIs in developing an effective RTQA program.
KW - Clinical trials
KW - Quality assurance
KW - Radiotherapy
KW - Recommendations
UR - http://www.scopus.com/inward/record.url?scp=105007293153&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2025.110950
DO - 10.1016/j.radonc.2025.110950
M3 - Review
C2 - 40412533
SN - 0167-8140
VL - 209
JO - Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
JF - Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
M1 - 110950
ER -